Compare Stocks: HYBT, GOSS, RZLTD, and ALGS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.21	$5.94	$3.98 ▼ $13.69	$38.78M	2.34	109,646 shs	20,253 shs
GOSS Gossamer Bio	$0.18	$0.17	$0.11 ▼ $3.87	$41.14M	2	20.98 million shs	8.06 million shs
HYBT Heyu Biological Technology	$0.10	$0.12	$0.00 ▼ $3.40	$10.34M	-17.74	5,371 shs	20 shs
RZLTD Rezolute	$4.58 +0.9%	$4.78	$16.00 ▼ $24.05	$38.55M	4.63	4,788 shs	716,948 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+5.97%	+11.09%	+20.82%	-45.24%
GOSS Gossamer Bio	0.00%	+3.12%	-1.52%	+9.56%	-94.04%
HYBT Heyu Biological Technology	0.00%	-14.44%	-27.33%	-19.92%	+19.02%
RZLTD Rezolute	0.00%	-0.87%	-2.35%	+12.25%	-42.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALGS Aligos Therapeutics	$6.21	$5.94	$3.98 ▼ $13.69	$38.78M	2.34	109,646 shs	20,253 shs
GOSS Gossamer Bio	$0.18	$0.17	$0.11 ▼ $3.87	$41.14M	2	20.98 million shs	8.06 million shs
HYBT Heyu Biological Technology	$0.10	$0.12	$0.00 ▼ $3.40	$10.34M	-17.74	5,371 shs	20 shs
RZLTD Rezolute	$4.58 +0.9%	$4.78	$16.00 ▼ $24.05	$38.55M	4.63	4,788 shs	716,948 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALGS Aligos Therapeutics	0.00%	+5.97%	+11.09%	+20.82%	-45.24%
GOSS Gossamer Bio	0.00%	+3.12%	-1.52%	+9.56%	-94.04%
HYBT Heyu Biological Technology	0.00%	-14.44%	-27.33%	-19.92%	+19.02%
RZLTD Rezolute	0.00%	-0.87%	-2.35%	+12.25%	-42.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALGS Aligos Therapeutics	2.86	Moderate Buy	$38.50	519.97% Upside
GOSS Gossamer Bio	2.22	Hold	$3.20	1,725.44% Upside
HYBT Heyu Biological Technology	0.00	N/A	N/A	N/A
RZLTD Rezolute	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HYBT, GOSS, RZLTD, and ALGS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/14/2026	GOSS Gossamer Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/11/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/10/2026	ALGS Aligos Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/28/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/28/2026	GOSS Gossamer Bio	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$1.00
7/27/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/10/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
6/25/2026	ALGS Aligos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/25/2026	GOSS Gossamer Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00 ➝ $2.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALGS Aligos Therapeutics	$2.19M	17.69	N/A	N/A	$8.67 per share	0.72
GOSS Gossamer Bio	$48.47M	0.85	N/A	N/A	($0.53) per share	-0.33
HYBT Heyu Biological Technology	$80K	129.19	N/A	N/A	$0.38 per share	0.26
RZLTD Rezolute	N/A	N/A	N/A	N/A	$1.24 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALGS Aligos Therapeutics	-$24.19M	-$7.30	N/A	N/A	N/A	-241.01%	-160.72%	-92.30%	11/5/2026 (Estimated)
GOSS Gossamer Bio	-$170.37M	-$0.70	N/A	N/A	N/A	-235.00%	N/A	-112.04%	11/4/2026 (Estimated)
HYBT Heyu Biological Technology	-$270K	N/A	N/A	N/A	N/A	-453.55%	-6.43%	-4.43%	N/A
RZLTD Rezolute	-$20.33M	N/A	N/A	N/A	N/A	N/A	-153.46%	-111.71%	N/A

Latest HYBT, GOSS, RZLTD, and ALGS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/13/2026	Q2 2026	GOSS Gossamer Bio	-$0.1234	-$0.08	+$0.0434	-$0.08	$3.63 million	$9.24 million
8/6/2026	Q2 2026	ALGS Aligos Therapeutics	-$1.09	-$0.14	+$0.95	-$0.14	$24.68 million	$27.78 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALGS Aligos Therapeutics	N/A	N/A	N/A	N/A	N/A
GOSS Gossamer Bio	N/A	N/A	N/A	N/A	N/A
HYBT Heyu Biological Technology	N/A	N/A	N/A	N/A	N/A
RZLTD Rezolute	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALGS Aligos Therapeutics	N/A	2.19	2.19
GOSS Gossamer Bio	N/A	0.53	0.53
HYBT Heyu Biological Technology	N/A	0.35	0.34
RZLTD Rezolute	N/A	3.26	3.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALGS Aligos Therapeutics	60.43%
GOSS Gossamer Bio	81.23%
HYBT Heyu Biological Technology	N/A
RZLTD Rezolute	N/A

Insider Ownership

Company	Insider Ownership
ALGS Aligos Therapeutics	7.80%
GOSS Gossamer Bio	3.74%
HYBT Heyu Biological Technology	89.24%
RZLTD Rezolute	4.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALGS Aligos Therapeutics	90	6.24 million	5.76 million	No Data
GOSS Gossamer Bio	180	234.70 million	225.92 million	Optionable
HYBT Heyu Biological Technology	6	103.25 million	11.11 million	Not Optionable
RZLTD Rezolute	23	8.42 million	N/A	Not Optionable

HYBT, GOSS, RZLTD, and ALGS Headlines

Recent News About These Companies

America/Resolute Time zone • Current Time in Resolute

November 11, 2023 | prokerala.comP

Rezolute (RZLT) Earnings Dates & Reports

November 9, 2023 | investing.com

Xilio Development Inc (XLO)

September 3, 2023 | investing.com

Systems Ltd.

August 9, 2023 | forbes.com

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

June 1, 2023 | benzinga.com

Analysts Are Bullish on These Healthcare Stocks: Rezolute (RZLT), Jazz Pharmaceuticals (JAZZ)

May 15, 2023 | markets.businessinsider.com

Rezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 12, 2023 | finanznachrichten.de

Rezolute Reports Third Quarter Fiscal 2023 Results and Highlights Company Progress

May 11, 2023 | finance.yahoo.com

Great news for Rezolute, Inc. (NASDAQ:RZLT): Insiders acquired stock in large numbers last year

April 25, 2023 | finance.yahoo.com

Rezolute (RZLT) Gets a Buy from H.C. Wainwright

March 28, 2023 | markets.businessinsider.com

Rezolute, Inc.: Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

February 12, 2023 | finanznachrichten.de

Rezolute Reports Second Quarter Fiscal 2023 Results and Highlights Company Progress

February 10, 2023 | finance.yahoo.com

Xeris Biopharma Holdings Stock (NASDAQ:XERS), Quotes and News Summary

February 7, 2023 | benzinga.com

After losing 37% in the past year, Rezolute, Inc. (NASDAQ:RZLT) institutional owners must be relieved by the recent gain

February 2, 2023 | finance.yahoo.com

Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED) and Rezolute (RZLT)

November 10, 2022 | markets.businessinsider.com

Rezolute to Present at the Jefferies London Healthcare Conference

November 1, 2022 | technews.tmcnet.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYBT, GOSS, RZLTD, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

$6.21 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

Gossamer Bio NASDAQ:GOSS

$0.18 0.00 (0.00%)

As of 09/4/2026 04:00 PM Eastern

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Heyu Biological Technology OTCMKTS:HYBT

$0.10 0.00 (0.00%)

As of 09/4/2026

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

Rezolute OTCMKTS:RZLTD

$4.58 +0.04 (+0.88%)

As of 09/4/2026

Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for rare and metabolic diseases in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It also develops RZ402, a small molecule plasma kallikrein inhibitor, which is in preclinical stage for the treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HYBT, GOSS, RZLTD, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HYBT, GOSS, RZLTD, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HYBT, GOSS, RZLTD, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYBT, GOSS, RZLTD, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Gossamer Bio NASDAQ:GOSS

Heyu Biological Technology OTCMKTS:HYBT

Rezolute OTCMKTS:RZLTD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest HYBT, GOSS, RZLTD, and ALGS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest HYBT, GOSS, RZLTD, and ALGS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

HYBT, GOSS, RZLTD, and ALGS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYBT, GOSS, RZLTD, and ALGS Company Descriptions

Aligos Therapeutics NASDAQ:ALGS

Gossamer Bio NASDAQ:GOSS

Heyu Biological Technology OTCMKTS:HYBT

Rezolute OTCMKTS:RZLTD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools